drugset / Trial / NCT00584935

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

NCT00584935 ↗

NaSingle-groupOpen-labelTreatment

Summary

Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These treatments, however, are not successful with all patients. Rituximab has been very effective in the treatment of other autoimmune disorders, and has recently been shown to be effective for autoimmune blistering pemphigus. We propose that it will also be effective in the treatment of cicatricial pemphigoid.

Timeline

Start
2006-01
Primary completion
2010-01
Completion
2026-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 1000 mg Intravenous